Selective serotonin reuptake inhibitors (SSRIs) not only prevent the accumulation of Aβ and Tau [15,16], but also reverse the emotional and cognitive deficits in AD patients and mouse models [17,18,19], indicating that targeting the serotonergic system could be an effective approach to treat cognitive and psychiatric symptoms of AD. This evidence concerns the gene MAPT and Alzheimer disease.